Zanini M

Language: Spanish
References: 4
Page: 67-68
PDF size: 187.26 Kb.

Text Extraction

No Abstract

REFERENCES

1. Evans EG. Causative pathogens in onychomycosis and the possibility of treatment resistance: a review. J Am Acad Dermatol 1998;38:S32-56.

2. De Backer M, De Vroey C, Lesaffre E, Scheys I, De Keyser P. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. J Am Acad Dermatol 1998;38:S57-63.

3. Elewski BE, Hay RJ. Update on the management of onychomycosis: highlights of the Third Annual International Summit on Cutaneous Antifungal Therapy. Clin Infect Dis 1996;23:305-13.

4. Lubeck DP, Gause D, Schein JR, Prebil LE, Potter LP. A health-related quality of life measure for use in patients with onychomycosis: a validation study. Qual Life Res 1999;8:121-9.